Introduction
============

The mammalian heart has very limited regenerative capacity after pathological injury due to the terminated cell proliferation of cardiomyocytes and the quiescent status of progenitor cells in adult hearts. During cardiac development in mammals, cardiomyocytes undergo the hyperplastic to hypertrophic transition before birth. Shortly after birth, the majority of cardiomyocytes withdraws from the cell cycle and becomes so-called terminally differentiated cells, though there is still a low rate of cardiomyocyte turnover [@B1], [@B2]. Emerging evidence indicates that adult heart may still maintain the regenerative potential, especially under certain pathological conditions because of the cell cycle reentry of cardiomyocytes and the existence of a small population of cells in adult hearts called cardiac stem cells (CSCs) or cardiac progenitor cells (CPCs).

miRNAs are a class of small non-coding RNA molecules regulating the stability or translational efficiency of targeted messenger RNAs [@B3]. More than 2,000 miRNA sequences have been identified or predicted from human origin tissues or cells [@B4]. miRNAs are mediated by RNA-induced silencing complex (RISC) that lead to base-pairing interactions between a miRNA and the binding site of its target mRNAs mostly within the 3\' untranslated region (3\'UTR). miRNAs regulate diverse biological processes including cell fate determination, cell cycle progression, stem cell self-renewal and differentiation [@B5]-[@B7].

A few miRNAs are found to be overexpressed in the heart including miR-1, miR-133, miR-208a, miR-208b, and miR-499. These miRNAs have been reported to play important roles in regulating cardiac development, cardiovascular diseases, as well as cardiac remodeling [@B8]. Cardiac-specific deletion of gene Dicer caused postnatal lethality from progressive heart failure, in which miRNA processing was interrupted and mature miRNAs were decreased in the heart [@B9]. In fact, miR-1 is one of the most abundant miRNAs in heart. The miR-1 family is expressed together with members of miR-133 family. The miR-1/133a bicistronic clusters (the miR-1-1/miR-133a-2 cluster and the miR-1-2/miR-133a cluster) are critical regulators of cardiac development. A specific enrichment of miR-1 was found in embryonic stem (ES) cell-derived cardiomyocytes, but not in ES cell derived smooth muscle cells and endothelial cells. Furthermore, miR-1 promotes cardiac differentiation. When miR-1 is overexpressed in human pluripotent stem cells, it will enhance the expression of key cardiac transcriptional factors and sarcomeric genes [@B10]. On the other hand, the miR-133 family is muscle-specific. Absence of miR-133a expression resulted in ectopic expression of smooth muscle genes in the heart and aberrant cardiomyocyte proliferation. It was reported that miR-133a-1 and miR-133a-2 double-mutant mice which survive to adulthood succumbed to dilated cardiomyopathy and heart failure [@B11]. These findings showed the importance of miRNAs in regulating cardiac development and cardiac diseases.

In this study, miR-708 was identified to be abundant in neonatal heart while the expression level markedly reduced in rat adult heart. Overexpression of miR-708 promoted cellular proliferation and protected cells against hypoxia-induced apoptosis in H9C2 cells and primary cardiomyocytes. Lipid nanoparticle delivery of miR-708 promoted myocardial regeneration and heart function recovery *in vivo*.

Results
=======

Identification of miR-708 as a cardiomyocytes-enriched miRNA in the heart of neonatal rat
-----------------------------------------------------------------------------------------

In comparison of the non-proliferative status of cardiomyocytes in adult heart, the cardiomyocytes in neonatal heart remain active, including ongoing cell division and rapid cell growth. In order to identify the key miRNAs in maintaining the active status of cardiomyocytes, quantitative real-time PCR-based miRNA profiling analyses were performed and compared in both neonatal and adult heart tissues of rat. As shown in Figure [1](#F1){ref-type="fig"}A and Supplemental Figure [S1](#SM1){ref-type="supplementary-material"}, a group of miRNAs was found to be differentially expressed in the neonatal hearts compared to adult hearts. 32 miRNAs were upregulated (Table [1](#T1){ref-type="table"}) and 18 miRNAs were downregulated (Table [2](#T2){ref-type="table"}) in the neonatal hearts compared to adult. Notably, a subset of miRNAs in Table [1](#T1){ref-type="table"}, such as miR-15b, miR-17-5p, miR-18a, miR-19a and miR-302e, has been previously reported to upregulate in heart during the neonatal period [@B12]-[@B14] (Figure [1](#F1){ref-type="fig"}B), demonstrating the consistency of our result with previous studies. In addition, our analysis showed that the miR-708 expression level is 10-15 times higher in neonatal than adult (Figure [1](#F1){ref-type="fig"}B).

In order to isolate and purify primary cardiomyocytes from the fresh neonatal heart tissues of rat, fibroblast cells were removed. The cells were further confirmed by immunofluorescence staining with cardiomyocytes-specific marker *cardiac troponin I* (cTnI) (Figure [1](#F1){ref-type="fig"}C), and quantitative RT-PCR analysis with cardiomyocytes-specific markers *cardiac muscle alpha actin* 1 (ACTC1), *cardiac muscle troponin T2*(cTnT2) and fibroblast-specific markers *fibroblast growth factor receptor 1*(FGFR1), *vimentin* (Figure [1](#F1){ref-type="fig"}D and [1](#F1){ref-type="fig"}E). miRNA analyses demonstrated the high level of miR-708 in cardiomyocytes while low in fibroblasts (Figure [1](#F1){ref-type="fig"}F). Similar results were observed for miR-1 and miR-133 (Figure [1](#F1){ref-type="fig"}F).

In order to compare the expression pattern of miR-708 in cardiomyocytes during heart development, hearts from day 14.5 embryos, neonatal and adult mice were collected and analyzed. As shown in Supplemental Figure [S2](#SM1){ref-type="supplementary-material"}, miR-708 was enriched in the hearts of embryos and neonatal mice, while decreased in adults.

miR-708 promoted the cellular proliferation of cardiomyocytes *in vitro*
------------------------------------------------------------------------

In order to determine the effect of miR-708 on cellular proliferation in heart, H9C2, a cardiomyocyte cell line derived from the embryonic rat hearts, was applied to overexpress miR-708 *in vitro*. As shown in Figure [2](#F2){ref-type="fig"}A, transfection of miR-708 mimics into H9C2 cells increased the level of miR-708 remarkably. A MTT assay demonstrated the increased cell proliferation in 24h and 48h after miR-708 mimic transfection (Figure [2](#F2){ref-type="fig"}B). In contrary, an antisense miR-708 inhibitor decreased the miR-708 levels in H9C2 cells and suppressed the cell proliferation (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D). Ki67 staining analysis indicated a higher Ki67 positive cell proportion in the miR-708 overexpressed H9C2 cells (Figure [2](#F2){ref-type="fig"}E and [2](#F2){ref-type="fig"}F). In addition to H9C2, primary cardiomyocytes isolated from the fresh heart tissues of neonatal rats were validated by staining with cardiomyocytes-specific marker α-actin 1, and transfected with miR-708 mimics followed by Ki-67 staining. As shown in Figures [2](#F2){ref-type="fig"}G and [2](#F2){ref-type="fig"}H, miR-708 promoted the proportion of α-actin / Ki-67 double positive cells.

miR-708 protected cardiomyocytes against apoptosis
--------------------------------------------------

In terms of the irreversible damage of myocardial tissue caused by myocardial infarction is partly due to the prolonged ischemia and lack of sufficient oxygen, the effect of miR-708 in response to hypoxia in H9C2 cells was determined. H9C2 cells were transfected with miR-708 mimics followed by culturing under the hypoxia condition of 1% oxygen for 24 hours. Annexin V analysis was applied to detect the apoptotic and dead cells. As shown in Figure [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B, overexpression of miR-708 protected H9C2 cells against apoptosis induced by hypoxia. In addition, H9C2 cells were treated with 200uM isoproterenol (ISO) which can induce myocardial infarction in animals, followed by analyses of cellular apoptosis and cell death. The majority of the miR-708 overexpressed H9C2 cells stayed alive after 24h treatment with ISO, while control cells underwent apoptosis and then died (Figure [3](#F3){ref-type="fig"}C). A quantitative analysis indicated significant decrease in the proportion of apoptotic cells induced by ISO from \~30% in control to 10-15% in miR-708 overexpressed H9C2 (Figure [3](#F3){ref-type="fig"}D and [3](#F3){ref-type="fig"}E).

Lipid nanoparticle delivery of miR-708 promoted myocardium regeneration and heart function recovery *in vivo*
-------------------------------------------------------------------------------------------------------------

In order to determine the effects of miR-708 *in vivo* on the cardiac regeneration after injury, a nonvirus delivery system was applied to deliver miR-708 mimics or a negative control to a mice model of heart injury induced by a daily treatment with 25mg/kg ISO through intraperitoneal injections for continuous 6 days. In Figure [4](#F4){ref-type="fig"}A, a neutral lipid emulsion (NLE) delivery reagent, which has been reported to be able to accumulate miRNAs in the heart [@B14] , was used to deliver miR-708 mimics to adult mice daily for 6 days via tail-vein injections. In order to confirm the delivery of miR-708 into the hearts, both instant and long-term effects after NLE-miR-708 injection were examined. As shown in Figure [4](#F4){ref-type="fig"}B, an immediate detection of the miR-708 levels in the heart, kidney and lung after 3-day\'s continuous delivery indicated the remarkable increase of miR-708 in all three tested tissues. In addition, long-term effect on the miR-708 expression in the hearts was determined at day 16 after the mice were anaesthetized. Compared to controls, miR-708 levels still kept a little bit higher in the hearts of NLE-miR-708 group (Figure [4](#F4){ref-type="fig"}C).

The heart function of the mice was evaluated at the indicated time points through echocardiography examinations (Figure [4](#F4){ref-type="fig"}A, 4D) and swimming test. ISO induced heart injury in mice was confirmed by echocardiography examination (Figure [4](#F4){ref-type="fig"}E). After anaesthetization of the mice at day 16, the histological HE staining of the hearts was performed (Supplemental Figure [S3](#SM1){ref-type="supplementary-material"}). miRNA analysis showed that ISO-induced heart injury was associated with increased miR-708 levels (Supplemental Figure [S4](#SM1){ref-type="supplementary-material"}), exaggerated chamber size, reduced Left ventricular contractility, decreased ejection fraction (EF%), decreased fractional shortening (FS%), increased left ventricular end diastolic volume (LVEDV) and increased left ventricular end systolic volume (LVESV), which were partly reversed by the application of miR-708 (Figure [4](#F4){ref-type="fig"}D-[4](#F4){ref-type="fig"}I, Supplemental Figure [S5](#SM1){ref-type="supplementary-material"}). The EF levels decreased from \~65% in PBS group to \~45% in ISO group, and returned to \~55% after miR-708 therapy (Figure [4](#F4){ref-type="fig"}F). Similar changes were observed on FS levels (Figure [4](#F4){ref-type="fig"}G). The increased levels of LVEDV and LVESV were seen in the heart at day 5 and day 10 after ISO treatment, which were rescued by local delivery of miR-708 (Figure [4](#F4){ref-type="fig"}H and [4](#F4){ref-type="fig"}I). A forced swim test at day 9 demonstrated the ISO-treated mice had much shorter swimming time than both PBS-treated mice and miR-708-treated ISO mice (Figure [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B), which reflected the functional recovery of the heart by local delivery of miR-708. The ratios of heart weight to body weight and heart weight to tibia length both showed significant decrease after treatment with miR-708 (Figure [5](#F5){ref-type="fig"}C). Wheat Germ Agglutinin (WGA) staining to the slides from paraffin-embedded heart tissue sections stained the cell membranes and extracellular matrix of cardiomyocytes. As shown in Figure [5](#F5){ref-type="fig"}D and [5](#F5){ref-type="fig"}E, the results indicated the cardiomyocyte hypertrophy induced by ISO, which was partly rescued by miR-708 therapy. Meanwhile, Masson\'s Trichrome Staining demonstrated the myocardial fibrosis induced by ISO, while miR-708 application protected the cardiomyocytes against fibrosis as shown in Figure [5](#F5){ref-type="fig"}F and [5](#F5){ref-type="fig"}G.

miR-708 suppressed Mapk14 expression in cardiomyocytes
------------------------------------------------------

In order to determine the mechanism by which miR-708 regulates myocardial regeneration in rodents, a bioinformatics screening analysis using miRNA target prediction tools including TargetScan, miRanda and PITA identified 200 genes as predicted targets of miR-708 in rat by all the three tools (Figure [6](#F6){ref-type="fig"}A). The gene list was further narrowed down through overlapping with 66 heart failure-related genes and 54 heart defects-related genes in rat, which led to a list of four genes, Mapk14, Casp3, Mapk3 and Ppar-α (Figure [6](#F6){ref-type="fig"}A). Quantitative real-time RT-PCR analyses demonstrated the decrease of mRNA levels of Mapk14, Casp3 and Mapk3 in cardiomyocytes after transfection with miR-708 (Figure [6](#F6){ref-type="fig"}B). Mapk14 mRNA was knocked down \~70% by miR-708. Notably, three binding sites to miR-708 were identified from the 3\'UTR of rat Mapk14 mRNA, in which the second binding site is highly conserved with the miR-708 binding site in the mouse Mapk14 mRNA (Supplemental Figure [S6](#SM1){ref-type="supplementary-material"}). A point mutation to the conserved binding site was applied (Figure [6](#F6){ref-type="fig"}C). Luciferase reporter vectors carrying either wild type or point mutated MAPK14 3\'UTR were assayed demonstrating the direct interaction between miR-708 and MAPK14 3\'UTR (Figure [6](#F6){ref-type="fig"}C and [6](#F6){ref-type="fig"}D). The decreased MAPK14 levels in the hearts and other tissues of mice upon the miR-708 delivery *in vivo* were confirmed at day 3 (Figure [6](#F6){ref-type="fig"}E) and day 16 (Figure [6](#F6){ref-type="fig"}F), which are consistent with the increased level of miR-708 (Figure [4](#F4){ref-type="fig"}B and [4](#F4){ref-type="fig"}C). Western blot further demonstrated the decrease of Mapk14 protein level by miR-708 in cardiomyocytes (Figure [6](#F6){ref-type="fig"}G and Supplemental Figure [S7](#SM1){ref-type="supplementary-material"}).

In order to determine whether miR-708 regulates myocardial regeneration through interaction with Mapk14, siRNA targeting rat Mapk14 was applied to H9C2 cells followed by miR-708 treatment and cell proliferation assays. As shown in Figure [6](#F6){ref-type="fig"}H and Supplemental Figure [S8](#SM1){ref-type="supplementary-material"}, Makp14 expression was knocked down by siRNA. MTT analyses confirmed the increase of cell proliferation by miR-708 only in control cells, but not in Mapk14 siRNA treated cells (Figure [6](#F6){ref-type="fig"}I), demonstrating the induction of cardiomyocyte cell proliferation by miR-708 is dependent at least partly on the expression of Mapk14.

Discussion
==========

In this study, we determined the differentially expressed miRNAs in neonatal hearts compared to adult hearts of rat. We found the overexpression of a subset of miRNAs in neonatal cardiomyocytes including miR-15b, miR-17-5p, miR-18a, miR-19a, miR-302e and miR-708. In consistent with our findings, there are studies reported the upregulation of the miR-15 family, the miR-17-92 cluster and the miR-302-367 cluster in heart during the neonatal period, and demonstrated the induction of cardiomyocyte proliferation and promotion of cardiac regeneration by enforced expression of these miRNAs [@B12]-[@B14]. Further than these reported miRNAs, we discovered some new miRNAs with potential to promote the proliferative ability of cardiomyocytes, such as miR-708.

Through an approach of enforced overexpression, miR-708 was demonstrated to promote proliferation of cardiomyocytes *in vitro*. Moreover, miR-708 protected cardiomyocytes against apoptosis induced by either hypoxia or ISO. The results from *in vivo* assay demonstrated that local delivery of miR-708 into ISO-induced heart injury mice promoted heart regeneration and increased recovery of heart function. For the local delivery system of miRNA, a neutral lipid emulsion delivery reagent was used in this study to effectively deliver exogenous miRNA mimics into the heart via tail-vein injections. This system was successfully reported to accumulate miRNAs in the heart [@B14] and validated in our present study. By histological analysis and gene expression analysis, neither long-term side effects nor off-target effects of miR-708 treatment *in vivo* were observed in the current study. These findings strengthen the potential of applying miRNAs to reconstitute lost cardiomyocytes in injured hearts, and provided a novel candidate of miRNA for promoting heart regeneration.

Cardiovascular disease is a leading cause of death over the world. As we know, the proliferation capability and turnover rate of cardiomyocytes in adult hearts are very low, the adult hearts have very limited potential for regeneration. The damaged myocardium usually undergoes degenerative remodeling process that leads to heart failure. Heart failure can be caused by many conditions which damage the heart muscle, including coronary artery disease, heart attack, cardiomyopathy, and conditions overloading work to the heart, for example, hypertension, kidney disease diabetes, etc. Although some progresses have been made in pharmacologic and device management as well as attempt of gene or cell therapy on heart failure, the mortality in heart failure patients remains significant, especially those patients over 65 years old.

Thus, the induction of cell-cycle reentry and cellular proliferation of adult cardiomyocytes may help maintaining the cardiac organ homeostasis and repair of the adult heart. Chen *et al* reported that the miR-17-92 cluster, as a critical regulator of cardiomyocyte proliferation, is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts [@B13]. While Porrello *et al* found that the miR-15 family contributes to postnatal loss of cardiac regenerative capacity. Inhibition of the miR-15 family from an early postnatal age until adulthood increases myocyte proliferation in the adult heart and improves left ventricular systolic function after adult myocardial infarction [@B15]. Our study reported here on the expression of miR-708 that induced proliferation of cardiomyocytes *in vitro*, and promoted regeneration of damaged heart*in vivo*.

We found that MAPK14 is a functional target of miR-708 in cardiomyocytes. The binding site to miR-708 in the 3\'UTR of mouse Mapk14 mRNA is highly conserved to one of the three miR-708 binding sites in rat Mapk14 mRNA. Luciferase reporter assay and gene expression analysis demonstrated that miR-708 suppresses MAPK14 expression, thereby reduces MAPK14 activity in cells. More specifically, we demonstrated that the function of miR-708 in regulation of cardiomyocyte proliferation was at least partly mediated by MAPK14. Whereas terminally differentiated cardiomyocytes in adult heart have diminished capacity to proliferate and regenerate. Emerging evidence indicated that MAPK14 is associated with cell cycle arrest in cardiomyocytes. Inhibition of MAPK14 activity can induce cell cycle reentry in adult myocytes. Therefore, MAPK14 inhibition by miR-708 or other molecules may represent a strategy to promote cardiac regeneration in response to injury [@B16]-[@B18].

In addition, MAPK14 is associated with apoptosis. Activation of MAPK14 by stress factors may lead to apoptosis by upregulating apoptosis-related proteins. It was suggested that MAPK14 activation is pro-apoptotic in cardiomyocytes. Increased activity of MAPK14 has been observed in animal models of heart failure and myocardial biopsies from heart failure patients. MAPK14 inhibitors reduce apoptosis in cardiac cells in response to several stimuli [@B19]-[@B21]. Regarding to our finding that miR-708 reduced stressor-induced apoptosis in cardiomyocytes, most likely the apoptosis regulation by miR-708 may be mediated by MAPK14.

In addition to MAPK14, in airway smooth muscle (ASM) cells, other genes such as CD38 and inflammation related cytokines including CCL11, CXCL10, CCL2 and CXCL8 were suppressed in expression by miR-708 overexpression [@B22], [@B23]. In term of function, miR-708 may regulate inflammation, contractility and proliferation of ASM cells by regulating JNK MAPK and MKP-1/PI3K/AKT signaling pathways [@B23]. These studies may be suggestive of the involvement of MAP kinase and PI3 kinase signaling during the miR-708-reguated cell proliferation in cardiomyocytes in addition to the inhibition of MAPK14, although further experimental confirmation is required.

Besides determination of the miR-708-MAPK14 interaction, cardiomyocyte proliferation was shown by Ki-67 immunostaining with heart tissue slides from the miRNA treated mice. Unfortunately no Ki-67+ cardiomyocytes were observed in adult hearts mainly due to the very limited proliferation capacity of adult cardiomyocytes. Thus, we think it is more likely that miR-708 may reactivate the quiescent progenitor cells and promote proliferation of the freshly differentiated cardiomyocytes in adult hearts. Although this has not been demonstrated yet by experimental assays *in vivo*, our previous work has indicated the differentiation induction of cardiac progenitor cells to cardiomyocytes *in vitro* [@B24].

In summary, our findings not only demonstrated miR-708 playing a key role in the regulation of cardiomyocyte proliferation, cardiac repair and regeneration, but also linked the function of miR-708 and MAPK14 in cardiomyocyte proliferation and apoptosis. Furthermore, it has potential for heart regeneration therapy.

Materials and Methods
=====================

Animals and Treatments
----------------------

Animal studies were approved by the Institutional Animal Care and Use Committee of the Tongji University for Laboratory Animal Medicine. Fisher (F344) rats were provided by Shanghai Lab. Animal Research Center \[SCXK (Shanghai)\]. 8- to 10-week-old C57BL/6J mice were purchased from Silaike Animal Company (Shanghai, China). Before treatment, all animals were screened for the baseline determination of echocardiography. Cardiac injury was induced by intraperitoneal injections of 25mg/kg of isoproterenol (Sigma) once daily for 6 days. Control animals received same volume of 1×PBS. Both isoproterenol and control mice were echocardiographed at day 0, 5, 10 and 15 to evaluate the heart function. At day 16, all mice were sacrificed; tissues were harvested for further analysis.

Cells and cell culture
----------------------

Cell line H9C2 was purchased from ATCC and maintained in DMEM medium with 10% of fetal bovine serum (FBS), penicillin (100U/ml) and streptomycin (100μg/ml). Cardiomyocytes from newborn rats or mice were prepared by collagenase II digestion and cultured in DMEM/M199 medium with 10% FBS, penicillin (100U/ml) and streptomycin (100μg/ml). The cardio fibroblasts and cardiomyocytes were separated using differential adhesion, and further confirmed by immunofluorescence staining with myocardial markers.

Oligos and transfection
-----------------------

All siRNAs, miR-708 mimic, anti-miR-708 and negative control oligoes were synthesized by GenScript (Nanjing, China). Primer sequences for quantitative analysis of mRNAs are available upon request. The target sequence for Mapk14 siRNA: 5\' GGACCTCCTTATAGACGAA 3\'. The target sequence for negative control siRNA: 5\' AGTCGCATACCTCGACAATAAT 3\'. The miRNA mimic sequences for WT and mutation miR-708 are: WT, 5\' AAGGAGCUUACAAUCUAGCUGGG 3\'; mutation, 5\' AUCGACCUUACUAUCUAGCUGGG 3\'. The HiPerFect transfection reagent from Qiagen was used for cell transfection following the manufacturer\'s instructions. Final concentration of 30 nM of small RNA oligoes was used for all *in vitro* assays.

miRNA QRT-PCR analysis
----------------------

An M&G miRNA Reverse Transcription Kit (miRGenes, Shanghai, China) was used to prepare the first strand cDNA of miRNAs following the manufacturer\'s instruction. 100ng of purified total RNA from each sample was used for miRNA measurement. After reverse transcription, the cDNA was diluted 1:1,000 for real-time PCR. Forward primer sequences for real-time PCR of miRNAs were: miR-1: 5\' cctggaatgtaaagaagtatg 3\'; miR-708: 5\' gagcuuacaaucuagcug 3\'; miR-15b: 5\' tagcagcacatcatggtt 3\'; miR-17-5p: 5\' caaagtgcttacagtgc 3\'; miR-18a: 5\' ggtgcatctagtgcagatag 3\'; miR-19a: 5\' cctgtgcaaatctatgcaa 3\'; miR-133a: 5\' tttggtccccttcaacc 3\' and 5s rRNA: 5\' agtacttggatgggagaccg 3\'. A universal reverse primer was provided by miRGenes. The SYBR Green Master Mix was purchased from ABI (Applied Biosystem, Life Technologies). The ABI 7900 HT Sequence Detection System (Applied Biosystem, Life Technologies) was used for quantitative real time PCR assay. 5s rRNA was used for normalization.

miRNA profiling analysis in neonatal and adult rat hearts
---------------------------------------------------------

Total RNA was isolated from hearts with Trizol reagent (Life Technologies). The cDNA was prepared as described above. The miRNA profiling analyses were performed with the quantitative real-time PCR based miRNA panel which contains 365 miRNAs and 5 reference small RNAs (miRGenes, Shanghai, China). The data was analyzed by Mev (version 4.9) software. p \<0.05 was considered as significant.

Western blot analysis
---------------------

Cell lysates (50μg) were separated by 10% SDS-PAGE. The proteins were transferred to nitrocellulose membrane. After blocking in 5% milk (w/v) at room temperature for one hour, the membranes were incubated at 4°C overnight with primary antibodies (1:2,000). Following PBST washing for three times with 10 min for each, the membranes were incubated with secondary antibodies (1:3,000) at room temperature for 1 hour followed by washing and staining. The antibodies below were used: anti-Mapk14 (\#9212, Cell Signaling) and anti-β-actin (sc-47778, Santa Cruz Biotechnology).

Cell proliferation assay
------------------------

4ⅹ10^3^cells/well were seeded into 96-well plate. At the indicated time points, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT) was used to stain cells for measuring cell proliferation.

Assessment of myocyte cross-sectional area
------------------------------------------

Slides from paraffin-embedded heart tissue were incubated with Alexa Fluor 488 conjugated wheat germ agglutinin (W11261, Fisher Scientific) for 45 minutes at room temperature. The mean cross-sectional area was calculated from \~150 cardiomyocytes in 5 randomly selected fields from 3 individual sections per group by using Image J software (National Institutes of Health, USA).

Masson staining
---------------

Slides from paraffin-embedded heart tissues were stained for fibrosis analysis with Masson\'s trichrome following standard method. The ratio of interstitial fibrosis to the total left ventricular area was calculated based on 20 randomly selected microscopic fields in three individual sections per group. Images were captured by a fluorescence microscopy (Leica, Germany), and analyzed with Image J software.

Immunofluorescence
------------------

Adherent cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 and then blocked with 1% BSA for 1h. After incubation with primary antibody (1:10 to 1:100 dilution) overnight at 4°C, FITC-conjugated goat anti rabbit IgG (ab6717, Abcam, 1:200 dilution) was used as secondary antibody. 6-diamidino-2-phenylindole (DAPI) was used for nuclear counterstaining. The slides were photographed using fluorescence microscopy (Leica, Germany). Primary antibodies: anti-cTnI (ab47003, Abcam), anti-Ki67 (ab15580, Abcam), anti-α-actin (A7811, Sigma).

Cellular apoptosis assay
------------------------

Cells were treated by either Hypoxia condition (1% O~2~, 94% N2, 5% CO~2~) for 24 hours or ISO (200μM) for 24 hours, followed by Annexin V staining and FACS analysis according to the manufacturer\'s instructions.

Systemic delivery of miRNA mimics using a neutral lipid emulsion
----------------------------------------------------------------

RNA-LANCER II lipid miR708 mimics and control were packaged as using MaxSuppressor in vivo RNA-LANCEr II (3410-01,Bioo Scientific) according to the manufacturer\'s instructions and delivered to adult mice (8 weeks old) with a daily dose of 0.4 mg/kg body weight NLE-formulated miRNA mimics via tail vein injection. To identify the effect of miRNA mimics on myocardial injury induced by ISO, miR-708 mimics or miRNA mimic control was administered daily for 6 days with ISO treatment.

Luciferase reporter assay
-------------------------

H9C2 cells were seeded on 12-well plates at a density of 1×10^5^ cells/well. Then cells were transfected using lipofectamine 2000 (Invitrogen) with 1.0 μg WT or mutated pMIR-Reporter Luciferase MAPK14 3\'UTR and 0.2μg of Renilla plasmid on the second day. 24 hours after transfection, luciferase activities were measured using Dual-Luciferase Reporter Assay System (Promega) by AutoLumat.

Statistical analysis
--------------------

Data are presented as mean ± SEM. The standard two-tailed student\'s *t*-test was used for analysis, in which p \<0.05 was considered statistical significant.
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![**miR-708 is enriched in cardiomyocytes of neonatal rats**. A: miRNA profiling analyses between three neonatal and three adult heart tissues in rats identified a subset of miRNAs including miR-708 with higher expression in the neonatal hearts compared to adults. A: adult, N: neonatal. B: The relative expression levels of indicated miRNAs in the hearts of neonatal rats and adult rats. C: Immunofluorescence staining of cardiomyocytes-specific marker cardiac troponin I (cTnI) in cardiomyocytes and fibroblast cells isolated from fresh hearts of neonatal rats. D: Quantitative analysis of fibroblast-specific markers *fibroblast growth factor receptor 1*(FGFR1) and *vimentin* in the isolated primary cardiomyocytes and fibroblast cells. E: Quantitative analysis of cardiomyocytes-specific markers *cardiac muscle alpha actin* 1 (ACTC1) and *cardiac muscle troponin T2*(cTnT2) in the isolated primary cardiomyocytes and fibroblast cells. F: A miRNA quantitative analysis demonstrated the high expression of miR-1, miR-133 and miR-708 in cardiomyocytes while low in fibroblasts. CM: cardiomyocytes, CF: cardiac fibroblast cells. Data are mean ± SEM (n=3). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g001){#F1}

![**miR-708 promoted the cellular proliferation of cardiomyocytes from neonatal rats**. A: Overexpression of miR-708 in H9C2 cells. B: MTT assays demonstrated the increased cell proliferation by miR-708 overexpression in H9C2 cells. C: Knockdown of miR-708 in H9C2 cells by anti-miR-708. D: Decreased cell proliferation by anti-miR-708 in H9C2 cells. E: Ki67 staining indicated a higher Ki67 positive cell proportion in miR-708 overexpressed H9C2 cells. F: Quantitative analysis of Ki67 positive cell proportion in E. G: α-actin and Ki67 staining indicated a higher Ki67 positive cell proportion in the miR-708 overexpressed primary cardiomyocyte cells (α-actin positive) isolated from fresh heart tissue of neonatal rats. H: Quantitative analysis of α-actin / Ki67 double positive cells in G. Data are presented as mean ± SEM (n=3). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g002){#F2}

![**miR-708 protected cardiomyocytes against apoptosis induced by hypoxia or isoproterenol.**A and B: H9C2 cells were cultured under the hypoxia condition of 1% oxygen for 24 hours with or without overexpression of miR-708, followed by Annexin V analyses (A). Bar graph showing decreased apoptotic cell percentage in the presentence of miR-708 (B). C: Pictures of H9C2 cell with or without overexpression of miR-708 showing different response to 200uM isoproterenol (ISO). Scale bar 50um. D and E: H9C2 cells were treated with 200uM ISO for 24 hours with or without overexpression of miR-708, followed by Annexin V analyses (D). Bar graph showing decreased apoptotic cell percentage in the presentence of miR-708 (E). Data are presented as mean ± SEM (n=3). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g003){#F3}

![**miR-708 promoted cardiac regeneration *in vivo*.**A: Schematic representation of the procedure to deliver miR-708 mimics or a negative control using a neutral lipid emulsion (NLE) reagent into the mice with heart injury induced by ISO (n=7 for each group). The effects of miR-708 on the cardiac regeneration and recovery of heart function *in vivo* were determined. B: Detection of the instant effects of NLE-miR-708 delivery *in vivo*indicating remarkable increase of miR-708 in the heart, kidney and lung after 3-day\'s continuous treatment. C: The long-term effects were determined by miR-708 analysis in the hearts at day 16 after the mice were anaesthetized, indicating a little bit higher of the miR-708 levels in the hearts of NLE-miR-708 group compared to controls. D: The echocardiography examinations indicated that ISO treatments exaggerated chamber size and reduced wall thicknesses compared with PBS treated mice, which were rescued by *in vivo* delivery of miR-708. E: Time course examinations of echocardiography showing the change of EF levels in mice within four weeks after ISO treatment. PBS was used as a negative control (n=5). F: Echocardiography examinations to the mice showing the EF levels decreased from \~65% in PBS group to \~45% in ISO group, and returned to \~55% after 6-day therapy with miR-708 mimics. G: Echocardiography examinations to the mice showing the FS levels decreased from \~35% in PBS group to \~22% in ISO group, and returned to \~30% after treatment with miR-708 mimics. H,I: The increased levels of LVEDV (H) and LVESV (I) were seen in the mice at day 5 and day10 after ISO treatment, which was rescued by *in vivo* delivery of miR-708. Data are presented as mean ± SEM (n=7). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g004){#F4}

![**miR-708 improved heart function *in vivo*.**A and B: A swimming test at day 9 demonstrated the ISO-treated mice had shorter swimming time within 3 min (A) and shorter swimming time before first break (B), compared to PBS control mice. miR-708 therapy improved significantly the swimming ability of the ISO-treated mice. C: miR-708 therapy decreased the ratios of heart weight to body weight and heart weight to tibia length in the ISO-treated mice. D: WGA staining showing the cardiomyocyte hypertrophy induced by ISO, which can be partly rescued by miR-708 treatment. E: Quantitative analysis of D. F: Masson\'s Trichrome Staining demonstrated the myocardial fibrosis induced by ISO, while miR-708 treatment protected the cardiomyocytes against fibrosis. G: Quantitative analysis of F. Data are presented as mean ± SEM (n≧3). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g005){#F5}

![**miR-708 regulates Mapk14 expression in cardiomyocytes.**A: Bioinformatics screening using TargetScan, miRanda and PITA predicted miR-708 target genes, which overlapped with 66 heart failure related genes and 54 heart defects related genes, deriving Mapk14, Casp3, Mapk3 and Ppar-α as candidate target genes of miR-708 in rat cardiomyocytes. B: Quantitative real-time RT-PCR analyses demonstrated the decrease of mRNA levels of Mapk14, Casp3 and Mapk3 by miR-708 overexpression in the primary cardiomyocytes isolated from the newborn rats. C: Sequences for the WT and point mutated MAPK14 3\'UTR. D: Luciferase reporter assays demonstrated the inhibition of MAKP14 3\'UTR by direct interaction with miR-708. E: Decreased MAPK14 levels in the hearts, kidneys and lungs of mice upon miR-708 delivery *in vivo* after three days\' miR-708 treatment. F: Decreased MAPK14 levels in the hearts of NLE-miR-708 treated mice at day 16. G: Western blot analyses demonstrating the decrease of Mapk14 protein level by miR-708 in cardiomyocytes. ß-actin served as loading control. H: Western blot analyses demonstrating the knockdown of Mapk14 by siRNA in H9C2 cells. ß-actin served as loading control. I: MTT analyses showed the increase of cell proliferation by miR-708 only in control H9C2 cells, but not in Mapk14 siRNA treated cells. Data are presented as mean ± SEM (n=3). \*p\<0.05, \*\*p\<0.01.](thnov07p1953g006){#F6}

###### 

Upregulated miRNAs in the hearts of neonatal rats compared to adult

  miRNA ID    Fold change (adult/neo)   p value   miRNA ID     Fold change (adult/neo)   p value
  ----------- ------------------------- --------- ------------ ------------------------- ---------
  miR-30c     0.454                     0.049     miR-490      0.243                     0.013
  miR-199a    0.433                     0.038     miR-191      0.239                     0.014
  miR-652     0.422                     0.033     miR-371b-3   0.224                     0.032
  miR-514-5   0.406                     0.029     miR-18a      0.214                     0.009
  miR-181b    0.405                     0.053     miR-18b      0.212                     0.006
  miR-548a    0.396                     0.012     miR-592      0.202                     0.002
  miR-503     0.394                     0.051     miR-483      0.185                     0.025
  miR-15b     0.363                     0.028     miR-148b     0.184                     0.023
  miR-107     0.355                     0.024     miR-455      0.182                     0.033
  miR-485     0.344                     0.002     miR-708      0.180                     0.054
  miR-106a    0.341                     0.017     miR-130b     0.153                     0.003
  miR-19a     0.333                     0.047     miR-487      0.146                     0.044
  miR-93      0.326                     0.015     miR-323b     0.129                     0.052
  miR-17-5    0.275                     0.036     miR-301a     0.081                     0.022
  miR-487b    0.271                     0.029     miR-302e     0.069                     0.044
  miR-127-3   0.260                     0.011     miR-136      0.066                     0.013

###### 

Downregulated miRNAs in the hearts of neonatal rats compared to adult

  miRNA ID   Fold change (adult/neo)   p value   miRNA ID   Fold change (adult/neo)   p value
  ---------- ------------------------- --------- ---------- ------------------------- ---------
  miR-29b    87.049                    0.000     miR-105    2.842                     0.044
  miR-29a    39.628                    0.007     miR-27a    2.774                     0.015
  miR-329    9.231                     0.012     miR-24     2.691                     0.022
  miR-150    9.162                     0.050     miR-222    2.662                     0.037
  miR-10a    4.483                     0.010     miR-23a    2.545                     0.025
  miR-517    3.900                     0.045     miR-208a   2.507                     0.001
  miR-497    3.757                     0.012     miR-192    2.472                     0.052
  miR-762    3.163                     0.021     miR-486    2.438                     0.054
  let-7b     3.006                     0.004     miR-27b    2.054                     0.046
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